These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24555772)

  • 1. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.
    Chiesa A; Lia L; Alberti S; Lee SJ; Han C; Patkar AA; Pae CU; Serretti A
    Int J Psychiatry Clin Pract; 2014 Jun; 18(2):97-102. PubMed ID: 24555772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.
    Hopkins SC; Reasner DS; Koblan KS
    Psychiatry Res; 2013 Aug; 208(3):285-7. PubMed ID: 23706899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting.
    Benedetti F; Colombo C; Pirovano A; Marino E; Smeraldi E
    Psychopharmacology (Berl); 2009 Mar; 203(1):155-60. PubMed ID: 18989660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
    Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
    Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
    Szegedi A; Rujescu D; Tadic A; Müller MJ; Kohnen R; Stassen HH; Dahmen N
    Pharmacogenomics J; 2005; 5(1):49-53. PubMed ID: 15520843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine 2 receptor C957T and catechol-o-methyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy.
    Huuhka K; Anttila S; Huuhka M; Hietala J; Huhtala H; Mononen N; Lehtimäki T; Leinonen E
    Neurosci Lett; 2008 Dec; 448(1):79-83. PubMed ID: 18929622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.
    Taranu A; Asmar KE; Colle R; Ferreri F; Polosan M; David D; Becquemont L; Corruble E; Verstuyft C
    Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):435-441. PubMed ID: 28627776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder.
    Narasimhan S; Aquino TD; Multani PK; Rickels K; Lohoff FW
    Psychiatry Res; 2012 Jun; 198(1):112-5. PubMed ID: 22417933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study.
    Schosser A; Calati R; Serretti A; Massat I; Kocabas NA; Papageorgiou K; Linotte S; Mendlewicz J; Souery D; Zohar J; Juven-Wetzler A; Montgomery S; Kasper S
    Eur Neuropsychopharmacol; 2012 Apr; 22(4):259-66. PubMed ID: 21940152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association analysis of the catechol-O-methyltransferase /methylenetetrahydrofolate reductase genes and cognition in late-onset depression.
    Wang X; Wang Z; Wu Y; Yuan Y; Hou Z; Hou G
    Psychiatry Clin Neurosci; 2014 May; 68(5):344-52. PubMed ID: 24373005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder.
    Houston JP; Kohler J; Ostbye KM; Heinloth A; Perlis RH
    Psychiatry Res; 2011 Oct; 189(3):475-7. PubMed ID: 21788083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of COMT, 5-HT(1A) , and SERT genetic polymorphisms on antidepressant response to Transcranial Magnetic Stimulation.
    Malaguti A; Rossini D; Lucca A; Magri L; Lorenzi C; Pirovano A; Colombo C; Smeraldi E; Zanardi R
    Depress Anxiety; 2011 Jul; 28(7):568-73. PubMed ID: 21449006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine receptor D2 and catechol-O-methyltransferase gene polymorphisms associated with anorexia nervosa in Chinese Han population: DRD2 and COMT gene polymorphisms were associated with AN.
    Peng S; Yu S; Wang Q; Kang Q; Zhang Y; Zhang R; Jiang W; Qian Y; Zhang H; Zhang M; Xiao Z; Chen J
    Neurosci Lett; 2016 Mar; 616():147-51. PubMed ID: 26808641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine.
    Benedetti F; Dallaspezia S; Colombo C; Lorenzi C; Pirovano A; Smeraldi E
    Eur Psychiatry; 2010 Dec; 25(8):476-8. PubMed ID: 20619611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMT and age at onset in mood disorders: a replication and extension study.
    Massat I; Kocabas NA; Crisafulli C; Chiesa A; Calati R; Linotte S; Kasper S; Fink M; Antonijevic I; Forray C; Snyder L; Bollen J; Zohar J; De Ronchi D; Souery D; Serretti A; Mendlewicz J
    Neurosci Lett; 2011 Jul; 498(3):218-21. PubMed ID: 21600957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
    Hwang JP; Yang CH; Tsai SJ
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):189-90. PubMed ID: 14758586
    [No Abstract]   [Full Text] [Related]  

  • 19. [The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine].
    Poirier MF
    Encephale; 1999 Jun; 25 Spec No 2():55-7; discussion 58-61. PubMed ID: 10434160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression.
    Hsiao CC
    Psychoneuroendocrinology; 2006 Aug; 31(7):839-46. PubMed ID: 16716529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.